AndersonR.J., SchrierR.W.: Clinical use of drugs in patients with kidney and liver disease.W.B. Saunders, Philadelphia, 1981.
3.
SmithJ.W., SeidlL.G., CluffL.E.: Studies on the epidemiology of adverse drug reactions.V. Clinical factors influencing susceptibility. Ann. Int. Med.65, 629, 1966.
4.
GrayT.K., AdamsL.L., FallonH.J.: Short-term intensive surveillance of adverse drug reactions.J. Clin. Pharmacol.13, 61, 1973.
5.
JickH.: Adverse drug effects in relation to renal function.Am. J. Med.62, 514, 1977.
6.
LevyM., LipshitzM., EliokinM.: Hospital admissions due to adverse drug reactions.Am. J. Med. Sci.277, 49, 1979.
7.
RichetG., Lopez de NovalesE., VerroustP.: Drug intoxication and neurologic episodes in chronic renal failure.Brit. Med. J.2, 394, 1970.
TaclobL., NeedleM.: Drug-induced encephalopathy in patients on maintenance hemodialysis.Lancet2, 704, 1976.
10.
SzetoH.H., InturrisiC.E., HoudeR., SaalS., CheighJ., ReidenbergM.M.: Accumulation of normoperidine, an active metabolite of mepiridine, in patients with renal failure or cancer.Ann. Int. Med.86, 738, 1977.
11.
FarringtonK., MillerP., VargheseZ., BaillodR.A., MoorheadJ.F.: Vitamin A toxicity and hypercalcemia in chronic renal failure.Brit. Med. J.282, 1999, 1981.
12.
McGeownM.G., DelargyH., TempleD.J.: Metabolism of flurazepam in patients with chronic renal failure: major urinary metabolite present in serum for up to three days after a single dose.Kidney Int.21, 669, 1982.
13.
BellJ.D., KincaidW.R., MorganR.G., BunieH., AlperinJ.B., SarlesH.E., RemmersA.R.: Serum ferritin assay and bone marrow in iron stores in patients on maintenance hemodialysis.Kidney Int.17, 237, 1981.
14.
WrightL.F., MyersW.D.: Medical management of home hemodialysis patients.Ann. Int. Med.89, 367, 1978.
15.
LazarusJ.M.: Complications in hemodialysis: an overview.Kidney Int.18, 783, 1980.
16.
BennettW.M., MutherR.S., ParkerR.A., FeigP., MorrisonG., GalperT.A., SingerI.: Drug therapy in renal failure: dosing guidelines for adults.Ann. Int. Med. 93, 62, 286, 1980.